Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BGM vs CVAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVAC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

CVAC Overall Winner 6-Pillar Tally: BGM 1 – 4 CVAC (1 Tie) Matrix Metrics: BGM 2 – 8 CVAC

As of Nov 19, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin).

  • Growth vs. Quality Trade-Off: CVAC earns the overall head-to-head edge with a stronger Unified Composite Score (60.2/100 BUY vs. BGM 59.6/100 HOLD) and 1.20β · 62% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs CVAC
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
CVAC NASDAQ Head-to-Head Winner
CureVac N.V. Ordinary Shares
Pharmaceutical Preparations
$4.66
-0.21% 1D
Market Cap $1.1B
TTM Revenue $71M
Forward P/E 5.2x
Beta / 30D Vol 1.20β · 62% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $4.64 · SMA50: $5.02

6-Pillar Scorecard Institutional Category Breakdown (BGM 1 – 4 CVAC)

Columns: Metric · BGM · CVAC
1. Valuation Multiples CVAC
Forward P/E N/M 5.2x
Trailing P/E N/M 7.0x
PEG Ratio N/M N/M
EV / Revenue 2.3x 14.9x
2. Growth & Scale CVAC
Revenue Growth (YoY) +69.8% -89.0%
Earnings Growth (YoY) +0.0% +24.0%
TTM Revenue (USD) $48M $71M
Market Cap $108.6M $1.1B
3. Profitability & Quality CVAC
Gross Margin 16.9% 93.3%
Operating Margin -23.4% 573.0%
Net Profit Margin -44.2% 182.1%
Return on Equity (ROE) -7.4% 40.2%
4. Balance Sheet & Cash Flow CVAC
Cash Generation (TTM) -$9.2M EBITDA $194M EBITDA
Cash Flow Margin -19.3% EBITDA Mgn N/A
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $5.65 Book/Sh · 40.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 63.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity 40.3% of Rev ($19M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (2) vs CVAC (8)
Institutional Metric BGM CVAC Criterion Row Edge
Market Capitalization
Scale
$108.6M $1.1B Larger Scale CVAC
Trailing P/E Ratio
Valuation
N/M 7.0x Lower Multiple CVAC
Forward P/E Ratio
Valuation
N/M 5.2x Lower Multiple CVAC
Revenue Growth (YoY)
Growth
+69.8% -89.0% Higher Growth BGM
Operating Margin (TTM)
Profitability
-23.4% 573.0% Higher Margin CVAC
Net Profit Margin
Profitability
-44.2% 182.1% Higher Margin CVAC
Return on Equity (ROE)
Capital Efficiency
-7.4% 40.2% Higher ROE CVAC
52-Week Range Position
Momentum
74% ($0–$11) 67% ($2–$6) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 1.20β · 62% Vol Lower Realized Risk CVAC
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 60.2 / 100 (BUY) Higher Composite CVAC
Trailing 12M Revenue (USD)
Operating Scale
$48M $71M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 93.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 14.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) $194M EBITDA ($5.65 Book/Sh · 40.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVAC +43.88 pp
BGM: -53.83% · CVAC: -9.95%
3M Horizon CVAC +53.56 pp
BGM: -64.12% · CVAC: -10.56%
6M Horizon CVAC +53.56 pp
BGM: -64.12% · CVAC: -10.56%
1Y Horizon CVAC +53.56 pp
BGM: -64.12% · CVAC: -10.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs CVAC. Trailing 12-month operating profitability (BGM -23.4% vs CVAC 573.0%) and valuation multiples (BGM N/M vs CVAC 5.2x Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
CVAC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$71M
Gross Margin93.3%
Op. Margin573.0%
ROE / Fwd P/E40.2% · 5.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 63.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
CVAC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 573.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs CVAC Key Questions & Quantitative Answers

As of Nov 19, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas CVAC carries 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin). Growth vs. Quality Trade-Off: CVAC earns the overall head-to-head edge with a stronger Unified Composite Score (60.2/100 BUY vs. BGM 59.6/100 HOLD) and 1.20β · 62% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

CVAC leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with CVAC at -89.0% YoY revenue growth and +24.0% YoY earnings growth on $71M TTM revenue (93.3% gross margin, 573.0% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $71M for CVAC. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVAC.

CVAC screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas CVAC trades at 5.2x Forward P/E, 7.0x Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus CVAC (40.2% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, CVAC carries 63.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.